In an update of the 19,490-patient Study of Tamoxifen and Raloxifene (STAR) P-2 trial in breast cancer prevention, both raloxifene and tamoxifen remain effective options to prevent breast cancer at 81 months of follow-up.
Raloxifene improved its effectiveness against noninvasive breast cancer, caused significantly less endometrial cancer and was significantly less toxic than tamoxifen. Although it was slightly less effective against invasive breast cancer, it still maintained strong efficacy.
Due to the late-breaking nature of these data, full results are being withheld until the trial is presented at the American Association for Cancer Research 101st Annual Meeting 2010 during a special plenary session in Hall D of the Walter E. Washington Convention Center at 10:00 a.m. ET on Monday, April 19, 2010. These results will be published simultaneously in Cancer Prevention Research, a journal of the AACR.
A panel of experts will be available to take questions from the media in room 142 of the convention center at 11:00 a.m. ET on April 19.
Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients